# ALX Oncology (stock symbol: ALXO) Logo in transparent PNG and SVG formats

## ALX Oncology Logo large

### ALX Oncology Logo large Download PNG (37.02 KB)

![ALX Oncology Logo large Download PNG (37.02 KB)](/img/orig/ALXO_BIG-961ae758.png)

### ALX Oncology Logo large Download SVG (3.53 KB)

![ALX Oncology Logo large Download SVG (3.53 KB)](/img/orig/ALXO_BIG-c758eeb3.svg)

## ALX Oncology Logo icon format

### ALX Oncology Logo icon format Download PNG (25.54 KB)

![ALX Oncology Logo icon format Download PNG (25.54 KB)](/img/orig/ALXO-81037f46.png)

### ALX Oncology Logo icon format Download SVG (753 Bytes)

![ALX Oncology Logo icon format Download SVG (753 Bytes)](/img/orig/ALXO-90d076e2.svg)

## ALX Oncology Logo large for dark backgrounds

### ALX Oncology Logo large for dark backgrounds Download PNG (24.82 KB)

![ALX Oncology Logo large for dark backgrounds Download PNG (24.82 KB)](/img/orig/ALXO_BIG.D-31b04139.png)

### ALX Oncology Logo large for dark backgrounds Download SVG (3.51 KB)

![ALX Oncology Logo large for dark backgrounds Download SVG (3.51 KB)](/img/orig/ALXO_BIG.D-1df3e176.svg)

## ALX Oncology Logo icon format for dark backgrounds

### ALX Oncology Logo icon format for dark backgrounds Download PNG (25.54 KB)

![ALX Oncology Logo icon format for dark backgrounds Download PNG (25.54 KB)](/img/orig/ALXO.D-4b01b128.png)

### ALX Oncology Logo icon format for dark backgrounds Download SVG (753 Bytes)

![ALX Oncology Logo icon format for dark backgrounds Download SVG (753 Bytes)](/img/orig/ALXO.D-5fadaa0a.svg)

## About ALX Oncology

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

1. Website domain: alxoncology.com
2. Employees: 52
3. Marketcap: $0.24 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
